FolioLanternBeta
VRTXVertex Pharmaceuticals · Insider ownership research

Vertex Pharmaceuticals insiders sold $158M in the past 12 months. How much of their stake is that?

About 28% overall. As a group they still hold 90% of their starting shares.

Updated Oct 9, 2026 from SEC filings · covers Oct 10, 2025 to Oct 9, 2026
How this comparesMore of their stake sold than at 459 of the 490 other companies we can measure (#32 of 491)See ranking
0
buyers among officers and directors, past 12 months
100%
of sales were under disclosed trading plans, past 12 months
13 of 24
officers and directors sold shares, past 12 months
Recent activity · past 30 days, Sep 10, 2026 to Oct 9, 2026

No officer or director trades were reported for the past 30 days. The most recent before that:

Aug 27, 2026Bruce Sachs gave away 6K shares as a gift. That is 13% of the total stake held that day.
WhoSharesPrice% of total stakeTotal stake afterTrade dateFiled
Bruce Sachs
Director
6,000n/a13%39KAug 27, 2026Aug 31, 2026

"% of total stake" is the shares in this event against all the vested shares the person held that day, across every share class and holding entity, after that day's vesting. "n/a" means the person's holdings don't reconcile, or the row is a purchase. "Holdings record incomplete" means more shares were sold than the filings show the person held that day, so a percentage would be wrong.

Is this normal? More than usual: about 1.8x the 5-year average. 13 insiders sold; the average is 12 a year. Year by year
Latest filing: Filed Sep 10 for a stock award on Sep 8. Jasper van Grunsven received an award of 8.7K shares. Filing
112 SEC ownership filings in the period · See the evidence

What stands out

Nine officers sold more than 25% of vested holdings: Reshma Kewalramani (34% of holdings, $19.7M, all under a disclosed plan), Carmen Bozic (76% of holdings, $11.3M, all under a disclosed plan) and Charles Wagner Jr. (46% of holdings, $10.8M, all under a disclosed plan), plus 6 more.Reshma Kewalramani: largest sale, Feb 27, 2026 · Carmen Bozic: largest sale, May 12, 2026 · Charles Wagner Jr.: largest sale, Jan 6, 2026
Sangeeta Bhatia sold 584 shares (13% of starting holdings), but 943 more vested, so the stake grew (from 4.6K to 4.9K).Largest sale, May 4, 2026

Percentages cover 20 of 24 officers and directors. 4 are left out

i
Left out: Amit Sachdev (most of their shares vested during the period, so a percentage would mislead); Jeffrey Leiden (most holdings were last confirmed in 2019); Michel Lagarde (most holdings were last confirmed in 2023); Jasper van Grunsven (held no vested shares at the start).
Disclosed company stock is not an insider's whole wealth.

Who sold, and how much of their stake

Officers and directors, past 12 months. Each bar is 100% of that person's own stake; not comparable between people. The stake is the vested shares held at the start of the period (Oct 9, 2025); the gold part is what they sold.

SoldRest of starting stake
Jeffrey Leiden
Executive Chairman, Director
Sold $60.9M (plan status beside the amount). That is 80% of the shares held or received (after tax withholding) during the period†. A share of the starting stake is not shown: most of these shares arrived during the period. Why
$60.9MDisclosed plan
Amit Sachdev
EVP Chief Patient & Ext Af Off
Sold $28.4M (plan status beside the amount). That is 45% of the shares held or received (after tax withholding) during the period†. A share of the starting stake is not shown: most of these shares arrived during the period. Why
$28.4MDisclosed plan
Reshma Kewalramani
CEO & President, Director
34% · $19.7MDisclosed plan
Carmen Bozic
EVP and CMO
76% · $11.3MDisclosed plan
Charles Wagner Jr.
EVP, Co & Fo
46% · $10.8MDisclosed plan
All 13 sellers

Selling by month

Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planOne dollar scale for every month; the tallest bar is labeled
OctNov 2025: $33.4M under a disclosed planNovDec 2025: $37.2M under a disclosed planDecJan 2026: $6.5M under a disclosed planJanFeb 2026: $64.4M under a disclosed plan$64.4MFebMar 2026: $5.1M under a disclosed planMarApr 2026: $439K under a disclosed planAprMay 2026: $5.3M under a disclosed planMayJun 2026: $3.7M under a disclosed planJunJul 2026: $2.0M under a disclosed planJulAugSepOct

Common questions

Is the Vertex Pharmaceuticals CEO selling stock?

Yes. Reshma Kewalramani sold 40K shares ($19.7M, 34% of starting holdings) in the past 12 months, all of it under a trading plan disclosed in the filings.

Why are Vertex Pharmaceuticals insiders selling?

Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 100% of sales by value ran under 10b5-1 trading plans disclosed in the filings. A trading plan schedules sales in advance.

Are any Vertex Pharmaceuticals insiders buying?

No. Officers and directors reported no purchases in the past 12 months.

How much of their stake did Vertex Pharmaceuticals insiders sell?

About 28% overall. As a group they still hold 90% of their starting shares. That covers the 12 months to Oct 9, 2026 and counts vested shares reported on SEC Forms 3, 4 and 5, which is not an insider's whole wealth.

The evidence

Who sold13 officers and directors: amount, % of holdings, trading plan
Who soldAmount% of holdingsTrading plan
Jeffrey Leiden
Executive Chairman, Director
$60.9M
137K shares
80%†
i
† Most of the shares Jeffrey Leiden sold arrived during the period, so this is shares sold as a share of the 24K held at the start plus the 154K received, less 6.5K withheld by the company for taxes.
Disclosed plan
Amit Sachdev
EVP Chief Patient & Ext Af Off
$28.4M
60K shares
45%†
i
† Most of the shares Amit Sachdev sold arrived during the period, so this is shares sold as a share of the 69K held at the start plus the 74K received, less 9.3K withheld by the company for taxes.
Disclosed plan
Reshma Kewalramani
CEO & President, Director
$19.7M
40K shares
34%Disclosed plan
Carmen Bozic
EVP and CMO
$11.3M
25K shares
76%Disclosed plan
Charles Wagner Jr.
EVP, Co & Fo
$10.8M
24K shares
46%Disclosed plan
Ourania Tatsis
EVP, Chief Reg. & Quality Off.
$6.5M
14K shares
27%Disclosed plan
Duncan McKechnie
EVP, Chief Commercial Officer
$5.7M
12K shares
71%Disclosed plan
Jonathan Biller
EVP and Chief Legal Officer
$3.8M
7.9K shares
51%Disclosed plan
Edward Atkinson III
EVP, Chief Technical Ops. Off.
$3.6M
7.8K shares
40%Disclosed plan
Mark Bunnage
EVP, Chief Scientific Officer
$3.0M
6.3K shares
39%Disclosed plan
Joy Liu
EVP and Chief Legal Officer
$2.1M
4.6K shares
20%Disclosed plan
Kristen Ambrose
SVP & Chief Accounting Officer
$2.0M
4.2K shares
53%Disclosed plan
Sangeeta Bhatia
Director
$268K
584 shares
13%Disclosed plan
The full ownership picture24 of 24 insiders fully reconciled · 23 officers and directors

Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.

InsiderHeld Oct 9, 2025SoldHeld Oct 9, 2026Still held
Reshma Kewalramani
i
Includes unvested RSUs, amount not disclosed.
CEO & President, Director
116K−40K98K85%
Vesting, gifts, unvested awards and holding lines for Reshma Kewalramani
0shares vested or exercised
0gifted (net of own trusts)
−33Kwithheld by the company for taxes
none reportedunvested awards, start → end
  • Includes unvested RSUs, amount not disclosed.
Held throughShare classOct 9, 2025Oct 9, 2026
Direct
includes unvested RSUs, amount not disclosed
Common Stock115,96898,278
Amit Sachdev
i
Minor difference of 87 shares. Difference is under 0.5% of holdings. Additional holdings last reported more than 3 years ago are shown separately and excluded from totals.
EVP Chief Patient & Ext Af Off
69K−60K74Knot meaningful
Vesting, gifts, unvested awards and holding lines for Amit Sachdev
+49Kshares vested or exercised
0gifted (net of own trusts)
−9.3Kwithheld by the company for taxes
none reportedunvested awards, start → end
  • Additional holdings last reported more than 3 years ago are shown separately and excluded from totals.
Held throughShare classOct 9, 2025Oct 9, 2026
DirectCommon Stock68,49066,512
401(k)Common Stock882882
Held in TrustCommon Stock06,637

Additional holdings last reported May 15, 2020, not confirmed since: 14,884 shares. Not included in any total or percentage on this page.

Reconciliation: minor difference of 87 shares. Difference is under 0.5% of holdings.

Stuart Arbuckle
i
Additional holdings last reported more than 3 years ago are shown separately and excluded from totals.
EVP, COO
64K064Kno sales
Vesting, gifts, unvested awards and holding lines for Stuart Arbuckle
0shares vested or exercised
0gifted (net of own trusts)
none reportedunvested awards, start → end
  • Additional holdings last reported more than 3 years ago are shown separately and excluded from totals.
Held throughShare classOct 9, 2025Oct 9, 2026
DirectCommon Stock63,36863,368
401(k)Common Stock140140

Additional holdings last reported Apr 28, 2017, not confirmed since: 140 shares. Not included in any total or percentage on this page.

Charles Wagner Jr.
i
Minor difference of 54 shares. Difference is under 0.5% of holdings.
EVP, Co & Fo
52K−24K47K91%
Vesting, gifts, unvested awards and holding lines for Charles Wagner Jr.
+9.5Kshares vested or exercised
0gifted (net of own trusts)
−12Kwithheld by the company for taxes
none reportedunvested awards, start → end
Held throughShare classOct 9, 2025Oct 9, 2026
DirectCommon Stock51,67147,042

Reconciliation: minor difference of 54 shares. Difference is under 0.5% of holdings.

Ourania Tatsis
i
Minor difference of 112 shares. Difference is under 0.5% of holdings.
EVP, Chief Reg. & Quality Off.
51K−14K54K+4.6%
Vesting, gifts, unvested awards and holding lines for Ourania Tatsis
0shares vested or exercised
0gifted (net of own trusts)
−9.9Kwithheld by the company for taxes
none reportedunvested awards, start → end
Held throughShare classOct 9, 2025Oct 9, 2026
DirectCommon Stock51,23953,572

Reconciliation: minor difference of 112 shares. Difference is under 0.5% of holdings.

Bruce Sachs
Director
45K039Kno sales
Vesting, gifts, unvested awards and holding lines for Bruce Sachs
0shares vested or exercised
−6Kgifted (net of own trusts)
15K → 16Kunvested awards, start → end
Held throughShare classOct 9, 2025Oct 9, 2026
DirectCommon Stock45,00039,000

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
11,250$127.54May 31, 2025$4.5M
3,142$399.71Apr 30, 2034$394K
2,398$502.97Apr 30, 2035$53K
2,866$424.45Apr 30, 2036$288K

Estimate: options held × ($524.99 − strike price), using the most recent insider trade price on Form 4 (Jul 2, 2026), not a market close.

Carmen Bozic
EVP and CMO
33K−25K15K47%
Vesting, gifts, unvested awards and holding lines for Carmen Bozic
0shares vested or exercised
0gifted (net of own trusts)
−9.3Kwithheld by the company for taxes
none reportedunvested awards, start → end
Held throughShare classOct 9, 2025Oct 9, 2026
DirectCommon Stock32,66915,337
Jeffrey Leiden
!
Most of this insider's holdings were last confirmed in 2019. Confirmed in the last three years: 35,237 shares. Not confirmed since: 106,635 shares, left out of this row. "Still held" is not shown because it would cover only the smaller, confirmed part.
Executive Chairman, Director
24K−137K35Ksee note
Vesting, gifts, unvested awards and holding lines for Jeffrey Leiden
+137Kshares vested or exercised
0gifted (net of own trusts)
−6.5Kwithheld by the company for taxes
none reportedunvested awards, start → end
  • Additional holdings last reported more than 3 years ago are shown separately and excluded from totals.
Held throughShare classOct 9, 2025Oct 9, 2026
DirectCommon Stock24,02634,797
401(k)Common Stock440440

Additional holdings last reported May 6, 2019, not confirmed since: 106,635 shares. Not included in any total or percentage on this page.

Joy Liu
i
Minor difference of 58 shares. Difference is under 0.5% of holdings. Started reporting during the period; starting holdings are from the Form 3. New Form 3 filed 2026-03-03; earlier filings set aside.
EVP and Chief Legal Officer
24K−4.6K19K81%
Vesting, gifts, unvested awards and holding lines for Joy Liu
0shares vested or exercised
0gifted (net of own trusts)
none reportedunvested awards, start → end
  • Started reporting during the period; starting holdings are from the Form 3.
  • New Form 3 filed 2026-03-03; earlier filings set aside.
Held throughShare classOct 9, 2025Oct 9, 2026
DirectCommon Stock23,70319,131

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
7,044$155.57Feb 5, 2028$2.6M
5,363$187.53Feb 5, 2029$1.8M

Estimate: options held × ($524.99 − strike price), using the most recent insider trade price on Form 4 (Jul 2, 2026), not a market close.

Reconciliation: minor difference of 58 shares. Difference is under 0.5% of holdings.

David Altshuler
i
Minor difference of 2 shares. Difference is under 0.5% of holdings.
EVP, Chief Scientific Officer
23K034Kno sales
Vesting, gifts, unvested awards and holding lines for David Altshuler
0shares vested or exercised
0gifted (net of own trusts)
none reportedunvested awards, start → end
Held throughShare classOct 9, 2025Oct 9, 2026
DirectCommon Stock23,28134,477

Reconciliation: minor difference of 2 shares. Difference is under 0.5% of holdings.

Edward Atkinson III
EVP, Chief Technical Ops. Off.
19K−7.8K18K95%
Vesting, gifts, unvested awards and holding lines for Edward Atkinson III
0shares vested or exercised
0gifted (net of own trusts)
−5.9Kwithheld by the company for taxes
none reportedunvested awards, start → end
Held throughShare classOct 9, 2025Oct 9, 2026
DirectCommon Stock19,35218,432
Duncan McKechnie
i
Minor difference of 61 shares. Difference is under 0.5% of holdings.
EVP, Chief Commercial Officer
16K−12K11K68%
Vesting, gifts, unvested awards and holding lines for Duncan McKechnie
0shares vested or exercised
0gifted (net of own trusts)
−5.4Kwithheld by the company for taxes
none reportedunvested awards, start → end
Held throughShare classOct 9, 2025Oct 9, 2026
DirectCommon Stock16,13011,001

Reconciliation: minor difference of 61 shares. Difference is under 0.5% of holdings.

Mark Bunnage
i
Minor difference of 33 shares. Difference is under 0.5% of holdings. Started reporting during the period; starting holdings are from the Form 3.
EVP, Chief Scientific Officer
16K−6.3K7.3K45%
Vesting, gifts, unvested awards and holding lines for Mark Bunnage
0shares vested or exercised
0gifted (net of own trusts)
−5.1Kwithheld by the company for taxes
none reportedunvested awards, start → end
  • Started reporting during the period; starting holdings are from the Form 3.
Held throughShare classOct 9, 2025Oct 9, 2026
DirectCommon Stock16,0627,284

Reconciliation: minor difference of 33 shares. Difference is under 0.5% of holdings.

Jonathan Biller
EVP and Chief Legal Officer
16K−7.9K14K87%
Vesting, gifts, unvested awards and holding lines for Jonathan Biller
0shares vested or exercised
0gifted (net of own trusts)
−7.3Kwithheld by the company for taxes
none reportedunvested awards, start → end
Held throughShare classOct 9, 2025Oct 9, 2026
DirectCommon Stock15,65313,659
Kristen Ambrose
SVP & Chief Accounting Officer
7.8K−4.2K12K+48%
Vesting, gifts, unvested awards and holding lines for Kristen Ambrose
0shares vested or exercised
0gifted (net of own trusts)
−3.1Kwithheld by the company for taxes
none reportedunvested awards, start → end
Held throughShare classOct 9, 2025Oct 9, 2026
DirectCommon Stock7,84511,624
Lloyd Carney
Director
7.1K06.3Kno sales
Vesting, gifts, unvested awards and holding lines for Lloyd Carney
0shares vested or exercised
−800gifted (net of own trusts)
none reportedunvested awards, start → end
Held throughShare classOct 9, 2025Oct 9, 2026
DirectCommon Stock7,1156,315

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
2,866$424.45Apr 30, 2036$288K

Estimate: options held × ($524.99 − strike price), using the most recent insider trade price on Form 4 (Jul 2, 2026), not a market close.

Alan Garber
Director
6.9K07.3Kno sales
Vesting, gifts, unvested awards and holding lines for Alan Garber
0shares vested or exercised
0gifted (net of own trusts)
0 → 65unvested awards, start → end
Held throughShare classOct 9, 2025Oct 9, 2026
DirectCommon Stock6,8727,344

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
3,142$399.71Apr 30, 2034$394K
1,199$502.97Apr 30, 2035$26K
1,433$424.45Apr 30, 2036$144K

Estimate: options held × ($524.99 − strike price), using the most recent insider trade price on Form 4 (Jul 2, 2026), not a market close.

Sangeeta Bhatia
Director
4.6K−5844.9K+7.9%
Vesting, gifts, unvested awards and holding lines for Sangeeta Bhatia
0shares vested or exercised
0gifted (net of own trusts)
none reportedunvested awards, start → end
Held throughShare classOct 9, 2025Oct 9, 2026
DirectCommon Stock4,5654,924
Diana McKenzie
Director
2.4K02.6Kno sales
Vesting, gifts, unvested awards and holding lines for Diana McKenzie
0shares vested or exercised
0gifted (net of own trusts)
7K → 7.8Kunvested awards, start → end
Held throughShare classOct 9, 2025Oct 9, 2026
DirectCommon Stock2,2312,378
Held in TrustCommon Stock207207
Suketu Upadhyay
Director
2.4K01.6Kno sales
Vesting, gifts, unvested awards and holding lines for Suketu Upadhyay
0shares vested or exercised
0gifted (net of own trusts)
2.6K → 3.6Kunvested awards, start → end
Held throughShare classOct 9, 2025Oct 9, 2026
DirectCommon Stock2,3541,558

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
2,866$424.45Apr 30, 2036$288K

Estimate: options held × ($524.99 − strike price), using the most recent insider trade price on Form 4 (Jul 2, 2026), not a market close.

Nancy Thornberry
Director
2K02.1Kno sales
Vesting, gifts, unvested awards and holding lines for Nancy Thornberry
0shares vested or exercised
0gifted (net of own trusts)
0 → 398unvested awards, start → end
Held throughShare classOct 9, 2025Oct 9, 2026
DirectCommon Stock2,0352,109

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
1,571$399.71Apr 30, 2034$197K
1,199$502.97Apr 30, 2035$26K
1,433$424.45Apr 30, 2036$144K

Estimate: options held × ($524.99 − strike price), using the most recent insider trade price on Form 4 (Jul 2, 2026), not a market close.

Jennifer Schneider
Director
1.7K01.4Kno sales
Vesting, gifts, unvested awards and holding lines for Jennifer Schneider
0shares vested or exercised
0gifted (net of own trusts)
0 → 796unvested awards, start → end
Held throughShare classOct 9, 2025Oct 9, 2026
DirectCommon Stock1,7181,394

Stock options (not counted as shares):

Options heldStrike priceExpiresIntrinsic value (estimate)
1,433$424.45Apr 30, 2036$144K

Estimate: options held × ($524.99 − strike price), using the most recent insider trade price on Form 4 (Jul 2, 2026), not a market close.

Jasper van Grunsven
EVP, CP and NPPO
008.7Kno sales
Vesting, gifts, unvested awards and holding lines for Jasper van Grunsven
0shares vested or exercised
0gifted (net of own trusts)
none reportedunvested awards, start → end
Held throughShare classOct 9, 2025Oct 9, 2026
DirectCommon Stock08,682

24 of 24 insiders fully reconciled: starting holdings plus reported transactions match ending holdings (17 exactly, 7 with a minor or footnoted difference). Percentages cover 20 of 24 officers and directors. Left out: Amit Sachdev (most of their shares vested during the period, so a percentage would mislead); Jeffrey Leiden (most holdings were last confirmed in 2019); Michel Lagarde (most holdings were last confirmed in 2023); Jasper van Grunsven (held no vested shares at the start). "Still held" compares ending with starting vested shares; a plus sign means the holding grew.

What explains the selling$158M of sales by plan status, purpose, seller and month

Officer and director open-market sales: $158M across 342,364 shares. Plan status and stated purpose are separate questions, and a sale can have both.

By plan status

Taxes

106,340 shares ($51.3M) were withheld by the company for taxes, which isn't a market sale.

SellerShares soldProceedsUnder a disclosed planShare of totalSales dates
Jeffrey Leiden
Executive Chairman, Director
137K$60.9M100%39%Nov 13, 2025 to Dec 3, 2025
Amit Sachdev
EVP Chief Patient & Ext Af Off
60K$28.4M100%18%Feb 19, 2026 to Feb 25, 2026
Reshma Kewalramani
CEO & President, Director
40K$19.7M100%12%Feb 27, 2026 to Feb 27, 2026
Carmen Bozic
EVP and CMO
25K$11.3M100%7%Feb 27, 2026 to Jun 26, 2026
Charles Wagner Jr.
EVP, Co & Fo
24K$10.8M100%7%Dec 3, 2025 to Jan 6, 2026
Ourania Tatsis
EVP, Chief Reg. & Quality Off.
14K$6.5M100%4%Dec 3, 2025 to Jul 2, 2026
Duncan McKechnie
EVP, Chief Commercial Officer
12K$5.7M100%4%Feb 25, 2026 to Jul 2, 2026
Jonathan Biller
EVP and Chief Legal Officer
7.9K$3.8M100%2%Dec 3, 2025 to Feb 25, 2026
Edward Atkinson III
EVP, Chief Technical Ops. Off.
7.8K$3.6M100%2%Nov 17, 2025 to Feb 25, 2026
Mark Bunnage
EVP, Chief Scientific Officer
6.3K$3.0M100%2%Feb 11, 2026 to May 15, 2026
Joy Liu
EVP and Chief Legal Officer
4.6K$2.1M100%1%Mar 2, 2026 to Jul 1, 2026
Kristen Ambrose
SVP & Chief Accounting Officer
4.2K$2.0M100%1%Feb 11, 2026 to Feb 26, 2026
Sangeeta Bhatia
Director
584$268K100%0.2%Feb 13, 2026 to May 4, 2026

Sales by month

MonthSale proceedsDisclosed planTo cover taxesNo plan disclosed
Oct 2025$0$0$0$0
Nov 2025$33.4M$33.4M$0$0
Dec 2025$37.2M$37.2M$0$0
Jan 2026$6.5M$6.5M$0$0
Feb 2026$64.4M$64.4M$0$0
Mar 2026$5.1M$5.1M$0$0
Apr 2026$439K$439K$0$0
May 2026$5.3M$5.3M$0$0
Jun 2026$3.7M$3.7M$0$0
Jul 2026$2.0M$2.0M$0$0
Aug 2026$0$0$0$0
Sep 2026$0$0$0$0
Oct 2026$0$0$0$0
Is this normal? Selling year by year5 earlier years to compare with

More than usual: about 1.8x the 5-year average. 13 insiders sold; the average is 12 a year.

12 months endingShares soldInsiders who soldProceeds
Oct 9, 2026
Latest 12 months
342K13$158M
Oct 9, 2025
1 year earlier
59K8$28.9M
Oct 9, 2024
2 years earlier
272K13$117M
Oct 10, 2023
3 years earlier
225K16$73.4M
Oct 10, 2022
4 years earlier
307K13$85.8M
Oct 10, 2021
5 years earlier
97K8$20.6M

Open-market sales (Form 4 code S) by people who were officers or directors, in split-adjusted shares. Earlier years include people who have since left. A sale that an outside holder also reports (a family trust, a fund) is counted with outside holders in every year. Shares, not dollars, are compared, so a change in the stock price doesn't look like a change in selling. Years the filings don't fully cover are shown but left out of the average.

Known gaps and uncertaintyEvery officer and director reconciles

Every officer and director reconciles for this period.

Amit Sachdev: minor difference of 87 shares. Difference is under 0.5% of holdings.

Charles Wagner Jr.: minor difference of 54 shares. Difference is under 0.5% of holdings.

Ourania Tatsis: minor difference of 112 shares. Difference is under 0.5% of holdings.

Joy Liu: minor difference of 58 shares. Difference is under 0.5% of holdings.

David Altshuler: minor difference of 2 shares. Difference is under 0.5% of holdings.

Duncan McKechnie: minor difference of 61 shares. Difference is under 0.5% of holdings.

Mark Bunnage: minor difference of 33 shares. Difference is under 0.5% of holdings.

Inferred rename: "Revocable Trusts" is treated as the same holder as "Revocable Trust", because the old name was never reported again and the new one opened with the same balance (5,568 shares). Old name, new name

Inferred rename: "10,061 shares 401(k); 207,500 shares in trust" is treated as the same holder as "10,106 shares 401(k); 207,500 shares in trust", because the old name was never reported again and the new one opened with the same balance (217,561 shares). Old name, new name

Inferred rename: "shares held in trust for Dr. Boger's children" is treated as the same holder as "shares in trust", because the old name was never reported again and the new one opened with the same balance (207,500 shares). Old name, new name

Inferred rename: "Shares in trust" is treated as the same holder as "Common stock held in children's trust", because the old name was never reported again and the new one opened with the same balance (207,500 shares). Old name, new name

Inferred rename: "401Ik)" is treated as the same holder as "401k", because the old name was never reported again and the new one opened with the same balance (13,286 shares). Old name, new name

Inferred rename: "owned by minor children" is treated as the same holder as "shares owned by minor children", because the old name was never reported again and the new one opened with the same balance (1,000 shares). Old name, new name

Inferred rename: "shares owned by minor children" is treated as the same holder as "minor child", because the old name was never reported again and the new one opened with the same balance (1,000 shares). Old name, new name

Inferred rename: "minor child" is treated as the same holder as "minor children", because the old name was never reported again and the new one opened with the same balance (1,000 shares). Old name, new name

Inferred rename: "minor children" is treated as the same holder as "Shares held by minor child", because the old name was never reported again and the new one opened with the same balance (1,000 shares). Old name, new name

Inferred rename: "401(k)" is treated as the same holder as "shares 401(k)", because the old name was never reported again and the new one opened with the same balance (1,316 shares). Old name, new name

Inferred rename: "Trust" is treated as the same holder as "Held in Trust", because the old name was never reported again and the new one opened with the same balance (207 shares). Old name, new name

Inferred typo: the share class "CommonStock" is treated as the same class as "Common Stock" on 1 holding line, because the two spellings are nearly identical and each balance carried over exactly. Example (Stuart Arbuckle, 34,553 shares): old title, new title

Inferred typo: the share class "Comon Stock" is treated as the same class as "Common Stock" on 1 holding line, because the two spellings are nearly identical and each balance carried over exactly. Example (Michael Parini, 36,832 shares): old title, new title

External context: we only cite outside events when a documented connection exists. None is shown for this period.

Sources and methodology2,554 filings from SEC EDGAR, and how we read them

All 2,554 Forms 3, 4 and 5 filed for Vertex Pharmaceuticals (SEC CIK 875320) from May 23, 2003 to Sep 10, 2026, retrieved from SEC EDGAR on Oct 9, 2026. Prices are the ones reported in each filing, often weighted averages. 6 filings were left out because Vertex Pharmaceuticals filed them as an owner of another company's stock.

Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.

Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".

Full methodology

Former or inactive filers (42)No filing in 18 months; last reported balances, not in any total
NameLast filedLast reported balance
Terrence KearneyMay 3, 20246,536 shares, last reported balance as of Aug 10, 2023
Bastiano SannaMay 9, 202332,038 shares, last reported balance as of May 8, 2023
Margaret McGlynnMay 3, 2023178 shares, last reported balance as of May 1, 2022
Yuchun LeeMay 3, 20231,875 shares, last reported balance as of Jan 27, 2023
Paul SilvaMar 2, 202121,972 shares, last reported balance as of Mar 1, 2021
Michael PariniFeb 26, 202130,837 shares, last reported balance as of Feb 25, 2021
William YoungJun 3, 20209,311 shares, last reported balance as of Jan 2, 2020
Elaine UllianJun 4, 201912,195 shares, last reported balance as of Jun 1, 2018
Thomas GraneyOct 2, 201812,430 shares, last reported balance as of Oct 1, 2018
Ian SmithJul 3, 201861,613 shares, last reported balance as of Jun 29, 2018
Jeffrey ChodakewitzFeb 14, 201869,663 shares, last reported balance as of Feb 12, 2018
Joshua BogerJun 9, 20171,452,043 shares, last reported balance as of Jun 8, 2017
Wayne RileyJun 3, 2015400 shares, last reported balance as of Mar 20, 2015
Thomas ConnollyDec 16, 201434,525 shares, last reported balance as of Dec 12, 2014
Kenneth HortonNov 19, 201472,419 shares, last reported balance as of Nov 17, 2014
Megan PaceNov 19, 201443,350 shares, last reported balance as of Nov 17, 2014
Peter MuellerJun 18, 2014172,308 shares, last reported balance as of Jun 16, 2014
Christiana StamoulisAug 1, 201341,651 shares, last reported balance as of Jul 15, 2013
Lisa KellyFeb 7, 201327,347 shares, last reported balance as of Feb 5, 2013
Matthew EmmensNov 20, 2012200,873 shares, last reported balance as of Nov 16, 2012
Nancy WysenskiJun 1, 201232,232 shares, last reported balance as of May 14, 2012
Dennis WingerMar 12, 201213,000 shares, last reported balance as of Mar 9, 2012
David HowtonFeb 6, 201219,703 shares, last reported balance as of Feb 2, 2012
Kenneth BogerSep 14, 2011303,275 shares, last reported balance as of Sep 13, 2011
Eugene CordesMar 18, 201112,000 shares, last reported balance as of Mar 17, 2011
Charles SandersJun 2, 201055,383 shares, last reported balance as of May 18, 2009
Stuart CollinsonJun 2, 20103,279 shares, last reported balance as of Dec 14, 2006
Roger BrimblecombeMar 16, 2010No balance on record
Kurt GravesOct 21, 200960,485 shares, last reported balance as of Oct 19, 2009
Richard GarrisonMay 19, 200938,782 shares, last reported balance as of May 18, 2009
Freda Lewis-HallMar 20, 200953,334 shares, last reported balance as of Mar 19, 2009
Eric BrandtJan 30, 2009No balance on record
John AlamOct 2, 2008141,932 shares, last reported balance as of Oct 1, 2008
Johanna PowerJul 25, 200814,406 shares, last reported balance as of Feb 7, 2008
Victor HartmannJun 5, 200799,495 shares, last reported balance as of Jun 4, 2007
Eve SlaterJun 4, 20071,105 shares, last reported balance as of May 29, 2007
Lynne BrumMay 9, 200659,805 shares, last reported balance as of May 8, 2006
Anthony ColesJul 22, 200577,843 shares, last reported balance as of Feb 3, 2005
Vicki SatoMay 12, 200592,396 shares, last reported balance as of May 11, 2005
Paul NegulescuFeb 7, 200556,832 shares, last reported balance as of Feb 3, 2005
John NiblackJun 2, 2004No balance on record
Iain BuchananMay 10, 200422,094 shares, last reported balance as of May 6, 2004

Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.